Due to the tumor-selective pattern of expression of SSX2, and the potent yet selective antigen-recognition properties of TCR-5, we decided to produce and test clinical-grade retroviral vectors suitable for the expression of TCR-5 in peripheral blood T cells of cancer patients. Here, SSX2 is linked to neoplasm.